Quintiles, London Genetics partner to improve drug discovery, development

Quintiles Global Central Laboratories senior vice president Thomas Wollman said that through their alliance with London Genetics, they have expertise to help early adopters of personalised medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world.

Under the non-exclusive alliance, Quintiles and London Genetics will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services.

Quintiles and London Genetics Ally said that by providing biopharma companies strategic advice on the application of pharmacogenetics and pharmacogenetics solutions, the companies can help customers access additional resources and speed the delivery of targeted treatments.

London Genetics CEO Dominique Kleyn said that their alliance will support biopharma in their interactions with academic partners and the development of personalized medicines.